HCM
AGTC

Highbridge Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Highbridge Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-17,724
Closed -$122K – 1709
2017
Q1 		$122K Sell
17,724
-2,697
-13% -$21.1K ﹤0.01% 1366
2016
Q4 		$191K Buy
+20,421
New +$184K ﹤0.01% 1142

Other funds holding AGTC

IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highbridge Capital Management's AGTC Position: Q2 2017 in Review

Highbridge Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2017, closing a stake of 17,724 shares — an estimated $122K sold.

Highbridge Capital Management first reported a position in AGTC in Q4 2016 and held it in 2 quarters. The position peaked at $191K in Q4 2016. 77 funds tracked by Wall St. Rank hold AGTC as of Q2 2017.

  • Highbridge Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 17,724 Applied Genetic Technologies Corporation shares in Q2 2017, an estimated $122K.
  • Highbridge Capital Management first reported a position in Applied Genetic Technologies Corporation in Q4 2016 and held it in 2 quarters.
  • Highbridge Capital Management's Applied Genetic Technologies Corporation position peaked at $191K in Q4 2016.
  • 77 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.